In lung cancer, the combination of the anti-PD-L1 antibody atezolizumab with the anti-VEGF TTmAb bevacizumab, associated with chemotherapy, has shown a benefit in terms of progression-free survival compared with the arm without atezolizumab (8.3 months vs. 6.8 months) [67]. The gene discussed is CD274; the disease is lung cancer.